Navigation Links
Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
Date:4/30/2008

SAN BRUNO, CA, April 30 C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1.

According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched Your Health Choice radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is its high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half.

Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone, says Dr. Raymond. C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses.

A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probiotic that is effective in fighting recurrent C. diff-associated disease1 Additionally, an article in the March 2006 issue of Gastroenterology and Hepatology showed that use of S. boulardii provided an almost 50 percent decrease in subsequent recurrence among patients who suffered recurrent CDAD symptoms.2 Because Florastor (S. boulardii) is a yeast and not a bacteria, it is not killed by the strong antibiotics that are being used to kill the C. diff bacteria, so it survives in the digestive tract, says Dr. Raymond. When the baby C. diff emerge from their spores, they are greeted by a well-colonized gut, rather than an empty playground.

CDAD is usually indicated by severe abdominal pain, diarrhea with mucous and blood passage, and fever. Dr. Raymond advises those exhibiting these symptoms to see a physician immediately to be tested for the presence of the C. diff toxins and to be prescribed proper antibiotics, since over-the-counter anti-diarrheal agents should be avoided.

Traditional OTC anti-diarrheal products actually slow down the speed of fluids moving through your bowels, and, in the case of C. diff, keeping the bacteria in the bowels is actually a bad thing, she adds.

Healthcare practitioners are advised to adhere to strict hand-washing policies in offices and hospitals to help prevent the spread of this and other types of bacteria.

Florastor has shown in more than 50 years of extensive international use to be safe and effective, with an estimated 1.7 billion daily doses sold to date. It is mentioned by the World Health Organization (WHO) for use in the management of C.diff-associated disease.3


'/>"/>

Contact: Christina Occhipinti
cocchipinti@robinleedyassociates.com
914-241-0086
Biocodex, Inc.
Source:Eurekalert

Related medicine news :

1. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
4. BASF Podcast: The Chemical Reporter - Why do You Get Garlic Breath?
5. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
6. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)
7. Mindray to Report First Quarter 2008 Financial Results on May 7, 2008
8. Kensey Nash Reports Third Quarter Record Revenue and Sales
9. Webcast Alert: HCA announces HCA 1Q 2008 Earnings Report
10. Landauer, Inc. Reports Record Results for Second Quarter
11. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: